| Today's Big NewsMay 1, 2023 |
| By James Waldron Big Pharma dealmaking may have remained relatively tepid in the first quarter, but some of the bigger European players used their earnings calls last week to suggest they may be turning on the spending taps later in the year. |
|
|
|
By Nick Paul Taylor The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche. |
By Max Bayer Ovid Therapeutics has taken another leap forward in its quest to treat seizures and rare brain disorders, buying into a clinical-stage Rock2 inhibitor from a biotech led by Sam Waksal, Ph.D. |
By Max Bayer Sanofi is betting up to $750 million to license a phase 2-ready treatment for Pompe disease from Maze Therapeutics. The deal includes $150 million in upfront cash and equity. |
By Helen Floersh An HIV drug from GSK or ones like it could have new therapeutic potential against neurodegenerative disease, findings in mice suggest. |
By Helen Floersh While targeted protein and RNA degradation are hot areas for R&D, the drugs developed so far come with limitations. Now, a new class with broader applications may not be far off. |
By Joseph Keenan Sanofi and Flatiron Health have inked a partnership to re-tool clinical trials focused on cancer treatments by leveraging more efficient transfers of data. |
By Zoey Becker The European pharmaceutical landscape could look a lot different in the next few years. In a proposal to revamp European pharma regulations, the European Commission aims to streamline its regulatory procedures and address certain problems in the market. |
By Ben Adams Two biotechs are making their old selves walk the plank as they take on new names in the hopes of a bounteous future. |
By Conor Hale The new Elevage Medical Technologies will follow the approach of Patient Square’s Enevate Sciences—which made its debut nearly a year ago to the day. |
By Angus Liu A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca and Merck's Lynparza in metastatic castration-resistant prostate cancer (mCRPC). A comment from FDA's oncology chief Rick Pazdur, M.D., likely played a crucial part in Friday's vote outcome. |
By Paige Minemyer Big payers continue to grow, and the compensation packages for their top brass are expanding alongside the companies. |
By Ben Adams Welcome to the breakdown of the top 10 biggest drug ad spenders in pharma for 2022 as we reveal who funneled the most cash into their campaigns. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we launch a special series on Narcan and progress for the opioid crisis. We also talk about why we need antimicrobial stewardship programs. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Connect with senior PR and communications leaders from big pharma, small-mid size pharma, biotech and more to gain insights and best practices on daily challenges in the industry. Save $500 when you Register Today!
|
|
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
